Infectious Disease and International Health

  • Carlos G. Grijalva, Keipp Talbot
    Funding Agency: CDC
    Grant Number: 75D30121C11656

    This multicenter project will evaluate the effectiveness of COVID and influenza vaccines in preventing household transmission of these infections

  • Carlos G. Grijalva, Wesley Self
    Funding Agency: CDC:
    Grant Number: 200-2016-91801

    This multicenter study will evaluate the effectiveness of COVID and influenza infections against hospitalization for these infections

  • Carlos G. Grijalva, Keipp Talbot
    Funding Agency: CDC: 
    Grant Number: 75D30121C11513

    This multicenter study will determine the effectiveness of vaccines for prevention of COVID and Influenza infections

  • Tina Hartert
    Funding Agency: NIH/NIAID 
    Grant Number: U19 AI 095227 

    Twelve city SARS-CoV-2 surveillance study of household units to understand immune response, transmission, symptomatology and role of asthma and allergies in infection. 

  • Staci Sudenga, Jessica Castilho
    Funding Agency: NCI: 
    Grant Number: P30CA068485

    Evaluate the potential biological importance of immunosenescence and risk of lung cancer among HIV-positive and -negative individuals

  • Christianne Roumie, Carlos G. Grijalva
    Funding Agency: AHRQ: 
    Grant Number: 1T32HS026122

    This training program provides support for personalized mentoring for projects related to the learning healthcare system paradigm.

  • Tina Hartert, MD, MPH, Thomas Braciale
    Funding Agency: NIH/NIAID
    Grant Number: R01 AI136526

    This study explores a novel hypothesis, extending evidence from animal studies and ecological data, that available and safe oral leukotriene modifying agents may decrease influenza-related morbidity and mortality and to corroborate the action in human lungs.

  • Carlos G. Grijalva
    Funding Agency: NIAID
    Grant Number:1K24AI148459

    This project provides support for mentoring on the transmission of respiratory viral infections in households.

  • Peter Rebeiro, Stephany Duda
    Funding Agency: NIAID
    Grant Number: R21-AI145686

    We propose to measure clinical and vital outcomes in the lost population through linkages between clinical data sources and well-established state/provincial or national registries. This tracing strategy of registry linkage has the benefit of being relatively low-cost and low-effort for clinical sites.

  • Staci Sudenga
    Funding Agency: NIAID
    Grant Number: R21-AI145686

    The disease burden of HIV is apparent worldwide despite primary prevention efforts. HPV infections have been shown to increase the risk for HIV in the few studies that have evaluated this association. We will evaluate if HPV infection at three different anatomic sites (anal, penile, and oral) increase the risk of HIV in men. Results from this study may help inform future HIV prevention research and policies.

  • Peter Rebeiro
    Funding Agency: NIAID
    Grant Number: K01-AI131895

    This research seeks to quantify health policy, sociodemographic, contextual, and geographic patterns and correlates of HIV Care Continuum outcomes among HIV-infected persons in the United States (US), Canada, and Mexico. Contextual factors include psychiatric illness, regional poverty, residential urbanicity, and other individual and environmental characteristics. The North American AIDS Cohort Collaboration on Research and Design (NA- ACCORD) and Caribbean, Central and South America network for HIV epidemiology (CCASAnet) provide rich data sources in which to conduct this work. Aim 1 will quantify disparities in Care Continuum outcomes in North and Latin America, assessing health system, demographic, risk, contextual, and geographic differences. Because research into the influence of contextual factors and health system characteristics on Care Continuum outcomes in longitudinal cohorts with clinical care data have been sparse or geographically limited, this analysis will be novel and of significant importance. Aims 2 and 3 will provide inferences about the ACA's effects on improving healthcare among HIV-infected individuals in care in the US. The state-led expansion of Medicaid coverage under the ACA will be used as a quasi-experiment to assess effects on Care Continuum and other HIV disease outcomes, comparing pre-ACA (pre-2014) to ACA implementation periods.

  • Staci Sudenga
    Funding Agency: NCI
    Grant Number: K07CA225404

    The proposed research project aims to evaluate the potential biological importance of tumor infiltrating lymphocytes (TILs) in patients with pre-malignant anal lesions and anal cancer. Through the career development award, Dr. Sudenga will develop skills in tumor immunology and cancer research to become an independent investigator in infection-related cancer epidemiology.

  • Wilbroad Mutale, MBChB, PhD, Douglas C Heimburger, MD, MS
    Funding Agency: NIH
    Grant Number: 5D43 TW009744

    UVP trains Zambian PhD- and postdoctoral HIV researchers, equipping them with research skills in non-communicable complications and comorbidities of HIV, while expanding the University of Zambia (UNZA) / University Teaching Hospital's (UTH) research training and investigative capacities.

  • Douglas C Heimburger, MD, MS Muktar Aliyu, MBBS, DrPH
    Funding Agency: NIH
    Grant Number: 2D43 TW009337

    Vanderbilt-Emory-Cornell-Duke (VECD) is one of six consortia that comprise the Fogarty Global Health Program for Fellows and Scholars. The purpose of this program is to provide mentored global health research training opportunities in low- and middle-income countries (LMICs) for pre- and post-doctoral candidates from the U.S. and LMICs. The program is sponsored by the Fogarty International Center (FIC) and several collaborating Institutes and Centers at the National Institutes of Health (NIH). Multiple training sites are available through VECD.

  • Tina Hartert, MD, MPH, Stokes Peebles, MD
    Funding Agency: NIH/NIAID
    Grant Number: U19 AI 095227

    We will use a combination of human natural quasi-randomization studies of infant RSV infection specifically designed to assess the impact of infant RSV infection on subsequent respiratory health and the airway epithelium, and in vitro models of RSV infection of nasal airway epithelial cells (NAECs). The overarching objectives of the 3 aims that will test these hypotheses are: 1) to determine whether the age of first infant RSV infection is associated with risk of subsequent incident recurrent wheeze and asthma; 2) to delineate the longitudinal effects of RSV on airway epithelial cell differentiation and metabolism throughout infancy and childhood; 3) to evaluate host gene  infant RSV infection interactions and RSV-dependent NAEC DNAm longitudinally to identify changes and temporal stability of RSV-dependent DNAm marks and their association with recurrent wheeze and asthma.